Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection.

Journal: JGH open : an open access journal of gastroenterology and hepatology
Published Date: Nov 28, 2017

Abstract

BACKGROUND AND AIM: Patients requiring hemodialysis show high morbidity with hepatitis C virus (HCV) infection, but there are difficulties associated with interferon-based therapies. Asunaprevir and daclatasvir could help patients with HCV genotype 1b because the drugs have a nonrenal metabolism and show good viral eradication. We evaluated the efficacy and safety of combined asunaprevir and daclatasvir therapy.

Authors

  • Taiga Otsuka
    Department of Internal Medicine, Division of Hepatology Saga University Hospital Saga Japan.
  • Yasunori Kawaguchi
    Hepato-Biliary and Pancreatology Division Saga Medical Center Koseikan Saga Japan.
  • Toshihiko Mizuta
    Department of Internal Medicine Imari-Arita Kyoritsu Hospital Saga Japan.
  • Yasushi Ide
    Department of Internal Medicine Karatsu Red Cross Hospital Saga Japan.
  • Futa Koga
    Department of Internal Medicine, Division of Hepatology Saga University Hospital Saga Japan.
  • Takanori Kumagai
    Department of Internal Medicine Taku City Hospital Saga Japan.
  • Wataru Yoshioka
    Department of Internal Medicine, Division of Hepatology Saga University Hospital Saga Japan.
  • Kenichiro Murayama
    Department of Internal Medicine, Division of Hepatology Saga University Hospital Saga Japan.
  • Osamu Rikitake
    Department of Internal Medicine Rikitake Clinic Saga Japan.
  • Yuji Ikeda
    Department of Internal Medicine, Division of Nephrology Saga University Hospital Saga Japan.
  • Iwata Ozaki
    Department of Internal Medicine, Division of Hepatology Saga University Hospital Saga Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals